Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Pharmacy benefit managers take different approaches to controlling ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...

Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

The Biologics Price Competition and Innovation Act of (BPCI Act) of 2009 granted responsibility to the FDA for review and approval of a new class of pharmaceuticals referred to as “Biosimilars.” (1) ...

Biosimilar market shares have risen, notably in oncology, ophthalmology, and pegfilgrastim, with significant FDA approvals enhancing competition. Adalimumab biosimilars struggle due to pharmacy ...

Across the U.S., debates surrounding the sustainability of our health care system show no signs of slowing. In 2023, the Centers for Medicare & Medicaid Services, or CMS, reported that health care ...

Biologics are medications made using living organisms. Biosimilars are FDA-approved biologic products that are highly similar to an existing biologic (the reference drug). Biologic and biosimilar ...

Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...

A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products and rare-disease therapies with smaller commercial footprints. Regulatory ...

Biosimilar drugs (also known as biosimilars, or follow-on biologics) are almost identical versions of a medical product or a drug that are produced by a different company to the parent company. They ...